Aprea therapeutics announces strategic ip portfolio evolution in dna damage response (ddr) cancer therapeutics

Doylestown, pa., feb. 05, 2025 (globe newswire) -- aprea therapeutics, inc. (nasdaq: apre) (“aprea”, or the “company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio.

DNA Ratings Summary

DNA Quant Ranking